Related Experiment Video
Updated: Aug 12, 2026

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
Membrane vesicles derived from Listeria monocytogenes might be a potential antigen delivery vector
Mingyuan Tang1, Sicheng Tian1, Kehan Chen1
1Department of Public Health Laboratory Sciences, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610061, China.
Abstract:
Membrane vesicles (MVs) derived from Listeria monocytogenes (LM) have a natural nanoscale size and contain a variety of bacterial components. We speculated that LM MVs may be a novel delivery vector, but it is necessary to evaluate the safety and immunogenicity of LM MVs in vivo. Here, we isolated LM MVs and tested their safety and immunogenicity both in vitro and in vivo. The results showed that LM MVs stimulated RAW264.7 cells and DC2.4 cells to secrete the inflammatory cytokines IL-1β, TNF-α, IL-6 and IL-10. Intraperitoneal injection of LM MVs at 80 μg per C57BL/6 mouse did not cause lethal effects or irreversible pathological changes in major organs, indicating that LM MVs were safe. Intraperitoneal immunization of C57BL/6 mice twice with LM MVs mainly induced a high level of LM MV-specific IgG antibodies. In addition, we subcutaneously injected C57BL/6 mice with a mixture of ovalbumin and LM MVs and found that LM MVs exhibited a humoral immune adjuvant effect equal to that of the same amount of alum. The results of this study indicated that LM MVs have good safety and effective immunogenicity and may act as humoral immune adjuvants. Therefore, LM MVs are a potential new choice for antigen and drug delivery vectors.
Insights
Listeria monocytogenes membrane vesicles (MVs) are safe and immunogenic, acting as effective humoral immune adjuvants. These MVs show potential as novel delivery vectors for antigens and drugs.
Area of Science:
- Bacteriology
- Immunology
- Nanotechnology
Background:
- Membrane vesicles (MVs) from Listeria monocytogenes (LM) are nanoscale and contain bacterial components.
- LM MVs are being investigated as potential novel delivery vectors.
- Safety and immunogenicity of LM MVs require in vivo evaluation.
Purpose of the Study:
- To assess the safety and immunogenicity of LM MVs in vitro and in vivo.
- To determine the potential of LM MVs as antigen and drug delivery vectors.
- To evaluate the adjuvant properties of LM MVs.
Main Methods:
- Isolation of LM MVs.
- In vitro stimulation of RAW264.7 and DC2.4 cells with LM MVs.
- In vivo safety assessment via intraperitoneal injection in C57BL/6 mice.
- In vivo immunogenicity testing through intraperitoneal immunization and subcutaneous co-injection with ovalbumin.
Main Results:
- LM MVs induced secretion of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in immune cells.
- Intraperitoneal injection of LM MVs showed no lethal effects or organ damage in mice, confirming safety.
- LM MVs induced high levels of LM MV-specific IgG antibodies after immunization.
- LM MVs demonstrated humoral immune adjuvant effects comparable to alum when co-injected with ovalbumin.
Conclusions:
- LM MVs possess good safety and effective immunogenicity.
- LM MVs can function as humoral immune adjuvants.
- LM MVs represent a promising new option for antigen and drug delivery vectors.
Related Concept Videos
Cross-reactivity
Formation of Lipopolysaccharides
Microbial Spoilage of Food
Sources of Food Contamination
Bacterial Meningitis
Bacterial Gastroenteritis

